<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Allergy</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Allergy</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский Аллергологический Журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1810-8830</issn><issn publication-format="electronic">2686-682X</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">9091</article-id><article-id pub-id-type="doi">10.36691/RJA9091</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original studies</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные исследования</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Levels of eosinophils and interleukin-5 and severity of atopic dermatitis in the presence of psychosocial stress</article-title><trans-title-group xml:lang="ru"><trans-title>Уровни эозинофилов, интерлейкина-5 и тяжесть течения атопического дерматита на фоне психосоциального стресса</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1409-504X</contrib-id><contrib-id contrib-id-type="spin">3914-7807</contrib-id><name-alternatives><name xml:lang="en"><surname>Prilutskiy</surname><given-names>Aleksandr S.</given-names></name><name xml:lang="ru"><surname>Прилуцкий</surname><given-names>Александр Сергеевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Med.), Professor</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор</p></bio><email>aspr@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2909-0682</contrib-id><contrib-id contrib-id-type="spin">6957-5817</contrib-id><name-alternatives><name xml:lang="en"><surname>Lygina</surname><given-names>Yuliya A.</given-names></name><name xml:lang="ru"><surname>Лыгина</surname><given-names>Юлия Андреевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD</p></bio><email>alikora21@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">M. Gorky Donetsk National Medical University</institution></aff><aff><institution xml:lang="ru">Донецкий национальный медицинский университет имени М. Горького</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2023-12-21" publication-format="electronic"><day>21</day><month>12</month><year>2023</year></pub-date><pub-date date-type="pub" iso-8601-date="2023-12-02" publication-format="electronic"><day>02</day><month>12</month><year>2023</year></pub-date><volume>20</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>415</fpage><lpage>428</lpage><history><date date-type="received" iso-8601-date="2023-05-04"><day>04</day><month>05</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-11-21"><day>21</day><month>11</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, Pharmarus Print Media</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, Фармарус Принт Медиа</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">Pharmarus Print Media</copyright-holder><copyright-holder xml:lang="ru">Фармарус Принт Медиа</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2026-02-02"/></permissions><self-uri xlink:href="https://rusalljournal.ru/raj/article/view/9091">https://rusalljournal.ru/raj/article/view/9091</self-uri><abstract xml:lang="en"><p><bold><italic>BACKGROUND:</italic></bold><italic> </italic>Skin damage in atopic dermatitis is caused by the participation of several immune cells and their inflammatory mediators. However, data on correlations between the severity of atopic dermatitis, combined with and without food allergies (severity of atopic dermatitis (SCORAD) index, etc.), and the levels of eosinophils and interleukin-5 are scarce and contradictory. No studies have compared the frequency of eczematous reactions occurring at different times or immediate allergic reactions in the above patients. Moreover, no studies or certain studies have reported results on the frequency of the combination of atopic dermatitis and food allergies, its various degrees of severity depending on these indicators, levels and relationships of the concentration of eosinophils, and interleukin-5 in the presence of psychosocial stress.</p> <p><bold><italic>AIM</italic></bold><italic>: </italic>To study the frequency and severity of the course, skin reactions in patients with atopic dermatitis, with and without food allergies, and levels and correlations of interleukin-5 and eosinophils in the presence of psychosocial stress in patients in the Donbass region.</p> <p><bold><italic>MATERIALS AND METHODS:</italic></bold><italic> </italic>A total of 165 patients with atopic dermatitis were examined. Questionnaire survey, anamnesis collection, and general clinical and specific allergological examinations were performed, and the levels of interleukin-5, absolute quantity, and percentage of eosinophils in the peripheral blood were determined. Two subgroups of patients with atopic dermatitis were analyzed: 1) those with food allergies and 2) those without food allergies. Persons living in areas with high and low shelling intensities were also identified. Data were statistically processed using the domestic program Medstat (Donetsk).</p> <p><bold><italic>RESULTS:</italic></bold><italic> </italic>In patients with atopic dermatitis, randomly selected from those who applied for an appointment with allergists-immunologists, this disease was combined with food allergy in 81.2% of cases. The severity of atopic dermatitis and eosinophil levels were significantly higher in the group with food allergies. Stable direct reliable correlations of varying strength have been established between the severity of atopic dermatitis (SCORAD index and its indicators) and the absolute quantity, percentage of eosinophils, and interleukin-5 level, as well as between the above laboratory parameters. Differences were found in the frequency of recording eczematous and immediate skin reactions. The residence of patients with atopic dermatitis with and without food allergies in areas that differed in shelling intensity was associated with the severity of atopic dermatitis and the level of eosinophils and interleukin-5.</p> <p><bold><italic>CONCLUSION:</italic></bold><italic> </italic>In most patients, atopic dermatitis is combined with food allergy, and the severity of its combination with food allergy increases. Therefore, reliable correlations of the SCORAD index with blood eosinophilia and interleukin-5 levels are revealed. The severity of atopic dermatitis and biomarkers in both subgroups increased when they lived in areas with high intensity of shelling.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Обоснование.</bold> Повреждение кожи при атопическом дерматите вызывается участием ряда иммунных клеток и выделяемых ими медиаторов. Однако данные о корреляциях тяжести течения атопического дерматита, сочетающегося с пищевой аллергией и без неё (индекс SCORAD и др.), с уровнем эозинофилов и интерлейкина-5 (IL-5) немногочисленны и противоречивы. Нет сравнительных результатов частоты экзематозных реакций, возникающих с различным интервалом времени, немедленных кожных аллергических реакций в вышеуказанных подгруппах больных. Отсутствуют или противоречивы исследования частоты сочетания атопического дерматита и пищевой аллергии, степени его тяжести в зависимости от этих показателей, уровня и связи с концентрацией эозинофилов, IL-5, в том числе в условиях психосоциального стресса.</p> <p><bold>Цель</bold> ― изучить частоту и тяжесть течения, кожные реакции, а также уровни и корреляционные связи IL-5 и эозинофилов у пациентов, проживающих в регионе Донбасса в условиях психосоциального стресса, страдающих атопичес-ким дерматитом, сочетающимся/не сочетающимся с пищевой аллергией.</p> <p><bold>Материалы и методы.</bold> Обследовано 165 пациентов с атопическим дерматитом. Проведены анкетирование, сбор анамнеза, общеклиническое и специфическое аллергологическое обследование, определены уровни IL-5, абсолютное количество и удельный вес эозинофилов в периферической крови. Выделены 2 подгруппы пациентов, у которых атопический дерматит либо сочетался, либо не имел сочетания с пищевой аллергией. Выделены также лица, проживающие на территориях с высокой и низкой интенсивностью обстрелов. Статистическая обработка данных проведена с использованием отечественной программы Medstat (Донецк).</p> <p><bold>Результаты.</bold> Установлено, что у 81,2% пациентов с атопическим дерматитом заболевание сочетается с пищевой аллергией. Степень тяжести течения атопического дерматита, уровни эозинофилов достоверно выше при сочетании с пищевой аллергией. Стабильные прямые достоверные корреляционные связи различной силы установлены между тяжестью атопического дерматита (индекс SCORAD и отдельные его показатели) и абсолютным количеством, удельным весом эозинофилов, уровнем IL-5, а также между вышеуказанными лабораторными показателями. Выявлены различия в частоте регистрации экзематозных, немедленных кожных реакций. Показано, что проживание пациентов с атопическим дерматитом, сочетающимся/не сочетающимся с пищевой аллергией, на территориях, различающихся по интенсивности обстрелов, связано с тяжестью течения атопического дерматита, уровнем эозинофилов и IL-5.</p> <p><bold>Заключение.</bold> У большинства больных атопический дерматит сочетается с пищевой аллергией, причём степень его тяжести при наличии пищевой аллергии повышается (выявляется достоверная корреляционная связь индекса SCORAD с уровнями эозинофилии крови и IL-5). Тяжесть атопического дерматита и биомаркеры в обеих подгруппах пациентов на территориях с высокой интенсивностью обстрелов увеличиваются.</p></trans-abstract><kwd-group xml:lang="en"><kwd>atopic dermatitis</kwd><kwd>allergy</kwd><kwd>food allergy</kwd><kwd>interleukin</kwd><kwd>interleukin-5</kwd><kwd>eosinophils</kwd><kwd>severity</kwd><kwd>stress</kwd><kwd>eczematous reactions</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>атопический дерматит</kwd><kwd>аллергия</kwd><kwd>пищевая аллергия</kwd><kwd>интерлейкин</kwd><kwd>IL-5</kwd><kwd>эозинофилы</kwd><kwd>тяжесть течения</kwd><kwd>стресс</kwd><kwd>экзематозные реакции</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Atopic dermatitis: Clinical recommendations (Approved by the Ministry of Health of the Russian Federation). Moscow: Russian Society of Dermatovenerologists and Cosmetologists, Russian Association of Allergologists and Clinical Immunologists, The Union of Pediatricians of Russia; 2021. (In Russ).</mixed-citation><mixed-citation xml:lang="ru">Атопический дерматит: клинические рекомендации (Утв. Минздравом Российской Федерации). Москва: Российское общество дерматовенерологов и косметологов, Российская ассоциация аллергологов и клинических иммунологов, Союз педиатров России, 2021.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Tsakok T, Marrs T, Mohsin M, et al. Does atopic dermatitis cause food allergy? A systematic review. J Allergy Clin Immunol. 2016;137(4):1071–1078. doi: 10.1016/j.jaci.2015.10.049</mixed-citation><mixed-citation xml:lang="ru">Tsakok T., Marrs T., Mohsin M., et al. Does atopic dermatitis cause food allergy? A systematic review // J Allergy Clin Immunol. 2016. Vol. 137, N 4. P. 1071–1078. doi: 10.1016/j.jaci.2015.10.049</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Papapostolou N, Xepapadaki P, Gregoriou S, Makris M. Atopic dermatitis and food allergy: A complex interplay what we know and what we would like to learn. J Clin Mede. 2022;11(14):4232. doi: 10.3390/jcm11144232</mixed-citation><mixed-citation xml:lang="ru">Papapostolou N., Xepapadaki P., Gregoriou S., Makris M. Atopic dermatitis and food allergy: A complex interplay what we know and what we would like to learn // J Clin Med. 2022. Vol. 11, N 14. P. 4232. doi: 10.3390/jcm11144232</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Wu ZH, Zhong J, Su CL, et al. Eosinophilia triggers changes in IL-5, eotaxin and IL-17, and acts as a prognostic biomarker for atopic dermatitis. Tropical J Pharmaceutical Res. 2017;16(5):1167–1172. doi: 10.4314/tjpr.v16i5.26</mixed-citation><mixed-citation xml:lang="ru">Wu Z., Zhong J., Su C.L., et al. Eosinophilia triggers changes in IL-5, eotaxin and IL-17, and acts as a prognostic biomarker for atopic dermatitis // Tropical J Pharmaceutical Res. 2017. Vol. 16, N 5. P. 1167–1172. doi: 10.4314/tjpr.v16i5.26</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Kimura M, Obi M, Saito M. Japanese cedar-pollen-specific IL-5 production in infants with atopic dermatitis. Int Arch Allergy Immunol. 2004;135(4):343–347. doi: 10.1159/000082330</mixed-citation><mixed-citation xml:lang="ru">Kimura M., Obi M., Saito M. Japanese cedar pollen-specific IL-5 production in infants with atopic dermatitis // Int Arch Alergy Immunol. 2004. Vol. 135, N 4. P. 343–347. doi: 10.1159/000082330</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Kimura M, Obi M. Ovalbumin-induced IL-4, IL-5 and IFN-gamma production in infants with atopic dermatitis. Int Arch Allergy Immunol. 2005;137(2):134–140. doi: 10.1159/000085792</mixed-citation><mixed-citation xml:lang="ru">Kimura M., Obi M. Ovalbumin-induced IL-4, IL-5 and IFN-gamma production in infants with atopic dermatitis // Int Arch Alergy Immunol. 2005. Vol. 137, N 2. P. 134–140. doi: 10.1159/000085792</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Gürkan A, Yücel AA, Sönmez C, et al. Serum cytokine profiles in infants with atopic dermatitis. Acta Dermatovenerol Croat. 2016;24(4):268–273.</mixed-citation><mixed-citation xml:lang="ru">Gürkan A., Yücel A.A., Sönmez C., et al. Serum cytokine profiles in infants with atopic dermatitis // Acta Dermatovenerol Croat. 2016. Vol. 24, N 4. P. 268–273.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Mizawa M, Yamaguchi M, Ueda C, et al. Stress evaluation in adult patients with atopic dermatitis using salivary cortisol. Biomed Res Int. 2013. doi: 10.1155/2013/138027</mixed-citation><mixed-citation xml:lang="ru">Mizawa M., Yamaguchi M., Ueda C., et al. Stress evaluation in adult patients with atopic dermatitis using salivary cortisol // Biomed Res Int. 2013. doi: 10.1155/2013/138027</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Renert-Yuval Y, Thyssen JP, Bissonnette R, et al. Biomarkers in atopic dermatitis: A review on behalf of the International Eczema Council. J Allergy Clin Immunol. 2021;147(4):1174–1190.e1. doi: 10.1016/j.jaci.2021.01.013</mixed-citation><mixed-citation xml:lang="ru">Renert-Yuval Y., Thyssen J.P., Bissonnette R., et al. Biomarkers in atopic dermatitis: A review on behalf of the International Eczema Council // J Allergy Clin Immunol. 2021. Vol. 147, N 4. P. 1174–1190.e1. doi: 10.1016/j.jaci.2021.01.013</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Hu Y, Liu S, Liu P, et al. Clinical relevance of eosinophils, basophils, serum total IgE level, allergen-specific IgE, and clinical features in atopic dermatitis. J Clin Lab Anal. 2020;34(6):e23214. doi: 10.1002/jcla.23214</mixed-citation><mixed-citation xml:lang="ru">Hu Y., Liu S., Liu P., et al. Clinical relevance of eosinophils, basophils, serum total IgE level, allergen-specific IgE, and clinical features in atopic dermatitis // J Clin Laboratory Analysis. 2020. Vol. 34, N 6. P. e23214. doi: 10.1002/jcla.23214</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Jenerowicz D, Czarnecka-Operacz M, Silny W. Peripheral blood eosinophilia in atopic dermatitis. Acta Dermatovenerol Alp Pannonica Adriat. 2007;16(2):47–52.</mixed-citation><mixed-citation xml:lang="ru">Jenerowicz D., Czarnecka-Operacz M., Silny W. Peripheral blood eosinophilia in atopic dermatitis // Acta Dermatovenerologica Alpina Panonica et Adriatica. 2007. Vol. 16, N 2. P. 47–52.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Eigenmann PA, Sicherer SH, Borkowski TA, et al. Prevalence of IgE-mediated food allergy among children with atopic dermatitis. Pediatrics. 1998;101(3):E8. doi: 10.1542/peds.101.3.e8</mixed-citation><mixed-citation xml:lang="ru">Eigenmann P.A., Sicherer S.H., Borkowski T.A., et al. Prevalence of IgE-mediated food allergy among children with atopic dermatitis // Pediatrics. 1998. Vol. 101, N 3. P. E8. doi: 10.1542/peds.101.3.e8</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">Calvani MA, Anania C, Caffarelli C, et al. Food allergy: An updated review on pathogenesis, diagnosis, prevention and management. Acta Biomed. 2020;91(Suppl 11):1–17. doi: 10.23750/abm.v91i11-S.10316</mixed-citation><mixed-citation xml:lang="ru">Calvani M., Anania C., Caffarelli C., et al. Food allergy: An updated review on pathogenesis, diagnosis, prevention and management // Acta Biomed. 2020. Vol. 91, Suppl. 11. Р. 1–17. doi: 10.23750/abm.v91i11-S.10316</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Kishkun AA. Clinical laboratory diagnostics: Textbook. 2nd revised and updated. Moscow: GEOTAR-Media; 2019. 1000 p. (In Russ).</mixed-citation><mixed-citation xml:lang="ru">Кишкун А.А. Клиническая лабораторная диагностика: учебное пособие. 2-е изд., перераб. и доп. Москва: ГЭОТАР-Медиа, 2019. 1000 с.</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Prilutsky AS. Development and use of innovative methods of immune pathology diagnosis and treatment. Arch Clin Exp Med. 2016;25(2):127–132.</mixed-citation><mixed-citation xml:lang="ru">Прилуцкий А.С. Разработка и использование инновационных методов диагностики и лечения иммунной патологии // Архив клинической и экспериментальной медицины. 2016. Т. 25, N 2. С. 127–132.</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">Koike Y, Takahashi N, Yada Y, et al. Selectively high level of serum interleukin 5 in a newborn infant with cow's milk allergy. Pediatrics. 2011;127(1):e231–234. doi: 10.1542/peds.2009-2318</mixed-citation><mixed-citation xml:lang="ru">Koike Y., Takahashi N., Yada Y., et al. Selectively high level of serum interleukin 5 in a newborn infant with cow's milk allergy // Pediatrics. 2011. Vol. 127, N 1. P. 231–234. doi: 10.1542/peds.2009-2318</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">Biancotto A, Wank A, Perl S, et al. Correction: Baseline levels and temporal stability of 27 multiplexed serum cytokine concentrations in healthy subjects. PLoS One. 2015;10(7):e0132870. doi: 10.1371/journal.pone.0132870</mixed-citation><mixed-citation xml:lang="ru">Biancotto A., Wank A., Perl S., et al. Correction: Baseline levels and temporal stability of 27 multiplexed serum cytokine concentrations in healthy subjects // PLoS One. 2015. Vol. 10, N 7. P. e0132870. doi: 10.1371/journal.pone.0132870</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">Bonett DG, Wright TA. Sample size requirements for estimating pearson, kendall and spearman correlations. Psychometrika. 2000;65(1):23–28. doi: 10.1007/BF02294183</mixed-citation><mixed-citation xml:lang="ru">Bonett D.G., Wright T.A. Sample size requirements for estimating pearson, kendall and spearman correlations // Psychometrika. 2000. Vol. 65, N 1. Р. 23–28. doi: 10.1007/BF02294183</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">Lyakh YE, Guryanov VG, Khomenko VN, Panchenko OA. Fundamentals of computer biostatistics: Analysis of information in biology, medicine and pharmacy with the statistical package MedStat. Donetsk: Papakitsa E.K.; 2006. 214 p. (In Russ).</mixed-citation><mixed-citation xml:lang="ru">Лях Ю.Е., Гурьянов В.Г., Хоменко В.Н., Панченко О.А. Основы компьютерной биостатистики: анализ информации в биологии, медицине и фармации статистическим пакетом MedStat. Донецк: Папакица Е.К., 2006. 214 с.</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">Tokura Y, Hayano S. Subtypes of atopic dermatitis: From phenotype to endotype. Allergol Int. 2022;71(1):14–24. doi: 10.1016/j.alit.2021.07.003</mixed-citation><mixed-citation xml:lang="ru">Tokura Y., Hayano S. Subtypes of atopic dermatitis: From phenotype to endotype // Allergol Int. 2022. Vol. 71, N 1. P. 14–24. doi: 10.1016/j.alit.2021.07.003</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">Celakovska J, Bukač J. Food hypersensitivity reactions and peripheral blood eosinophilia in patiens suffering from atopic dermatitis. Food Agric Imunol. 2017;28:35–43. doi: 10.1080/09540105.2016.1202209</mixed-citation><mixed-citation xml:lang="ru">Celakovska J., Bukac J. Food hypersensitivity reactions and peripheral blood eosinophilia in patients suffering from atopic dermatitis // Food Agricultural Immunol. 2017. Vol. 28, N 1. P. 35–43. doi: 10.1080/09540105.2016.1202209</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">Kondo S, Yazawa H, Jimbow K. Reduction of serum interleukin-5 levels reflect clinical improvement in patients with atopic dermatitis. J Dermatol. 2001;28(5):237–243. doi: 10.1111/j.1346-8138.2001.tb00124.x</mixed-citation><mixed-citation xml:lang="ru">Kondo S., Yazawa H., Jimbow K. Reduction of serum interleukin-5 levels reflect clinical improvement in patients with atopic dermatitis // J Dermatol. 2001. Vol. 28, N 5. P. 237–243. doi: 10.1111/j.1346-8138.2001.tb00124.x</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><citation-alternatives><mixed-citation xml:lang="en">Antúnez C, Torres MJ, Mayorga C, et al. Different cytokine production and activation marker profiles in circulating cutaneous-lymphocyte-associated antigen T cells from patients with acute or chronic atopic dermatitis. Clin Exp Allergy. 2004;34(4):559–566. doi: 10.1111/j.1365-2222.2004.1933.x</mixed-citation><mixed-citation xml:lang="ru">Antúnez C., Torres M.J., Mayorga C., et al. Different cytokine production and activation marker profiles in circulating cutaneous-lymphocyte-associated antigen T cells from patients with acute or chronic atopic dermatitis. // Clin Exp Allergy. 2004. Vol. 34, N 4. P. 559–566. doi: 10.1111/j.1365-2222.2004.1933.x</mixed-citation></citation-alternatives></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">А Raap U, Werfel T, Jaeger B, Schmid-Ott G. [Atopic dermatitis and psychological stress. (In German)]. Hautarzt. 2003;54(10):925–929. doi: 10.1007/s00105-003-0609-z</mixed-citation><mixed-citation xml:lang="ru">Raap U., Werfel T., Jaeger B., Schmid-Ott G. [Atopic dermatitis and psychological stress. (In German).] // Hautarzt. 2003. Vol. 54, N 10. P. 925–929. doi: 10.1007/s00105-003-0609-z</mixed-citation></citation-alternatives></ref><ref id="B25"><label>25.</label><citation-alternatives><mixed-citation xml:lang="en">Akan A, Azkur D, Civelek E, et al. Risk factors of severe atopic dermatitis in childhood: Single-center experience. Turk J Pediatr. 2014;56(2):121–126.</mixed-citation><mixed-citation xml:lang="ru">Akan A., Azkur D., Civelek E., et al. Risk factors of severe atopic dermatitis in childhood: Single-center experience // Turkish J Pediatr. 2014. Vol. 56, N 2. P. 121–126.</mixed-citation></citation-alternatives></ref><ref id="B26"><label>26.</label><citation-alternatives><mixed-citation xml:lang="en">Holm JG, Hurault G, Agner T, et al. Immunoinflammatory biomarkers in serum are associated with disease severity in atopic dermatitis. Dermatology. 2021;237(4):513–520. doi: 10.1159/000514503</mixed-citation><mixed-citation xml:lang="ru">Holm J.G., Hurault G., Agner T., et al. Immunoinflammatory biomarkers in serum are associated with disease severity in atopic dermatitis // Dermatology. 2021. Vol. 237, N 4. P. 513–520. doi: 10.1159/000514503</mixed-citation></citation-alternatives></ref><ref id="B27"><label>27.</label><citation-alternatives><mixed-citation xml:lang="en">Bacharier LB, Jackson DJ. Biologics in the treatment of asthma in children and adolescents. J Allergy Clin Immunol. 2023;151(3):581–589. doi: 10.1016/j.jaci.2023.01.002</mixed-citation><mixed-citation xml:lang="ru">Bacharier L.B., Jackson D.J. Biologics in the treatment of asthma in children and adolescents // J Allergy Clin Immunol. 2023. Vol. 151, N 3. P. 581–589. doi: 10.1016/j.jaci.2023.01.002</mixed-citation></citation-alternatives></ref><ref id="B28"><label>28.</label><citation-alternatives><mixed-citation xml:lang="en">Global Initiative for Asthma [Internet]. Global Strategy for Asthma Management and Prevention. GINA; Fontana, WI, USA; 2002. Available from: https://ginasthma.org/. Accessed: 06.07.2023.</mixed-citation><mixed-citation xml:lang="ru">Global Initiative for Asthma [Internet]. Global Strategy for Asthma Management and Prevention. GINA; Fontana, WI, USA, 2002. Режим доступа: https://ginasthma.org/. Дата обращения: 06.07.2023.</mixed-citation></citation-alternatives></ref><ref id="B29"><label>29.</label><citation-alternatives><mixed-citation xml:lang="en">Butala S, Castelo-Soccio L, Seshadri R, et al. Biologic versus small molecule therapy for treating moderate to severe atopic dermatitis: Clinical considerations. J Allergy Clin Immunol Pract. 2023;11(5):1361–1373. doi: 10.1016/j.jaip.2023.03.011</mixed-citation><mixed-citation xml:lang="ru">Butala S., Castelo-Soccio L., Seshadri R., et al. biologic versus small molecule therapy for treating moderate to severe atopic dermatitis: Clinical considerations // J Allergy Clin Immunol Pract. 2023. Vol. 11, N 5. P. 1361–1373. doi: 10.1016/j.jaip.2023.03.011</mixed-citation></citation-alternatives></ref><ref id="B30"><label>30.</label><citation-alternatives><mixed-citation xml:lang="en">Torrelo A, Rewerska B, Galimberti M, et al. Efficacy and safety of baricitinib in combination with topical corticosteroids in pediatric patients with moderate-to-severe atopic dermatitis with inadequate response to topical corticosteroids: Results from a phase 3, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS). Br J Dermatol. 2023:189(1):23–32. doi: 10.1093/bjd/ljad096</mixed-citation><mixed-citation xml:lang="ru">Torrelo A., Rewerska B., Galimberti M., et al. Efficacy and safety of baricitinib in combination with topical corticosteroids in pediatric patients with moderate-to-severe atopic dermatitis with inadequate response to topical corticosteroids: Results from a phase 3, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS) // Br J Dermatol. 2023. Vol. 189, N 1. P. 23–32. doi: 10.1093/bjd/ljad096</mixed-citation></citation-alternatives></ref><ref id="B31"><label>31.</label><citation-alternatives><mixed-citation xml:lang="en">Makowska K, Nowaczyk J, Blicharz L, et al. Immunopathogenesis of atopic dermatitis: Focus on interleukins as disease drivers and therapeutic targets for novel treatments. Int J Mol Sci. 2023;24(1):781. doi: 10.3390/ijms24010781</mixed-citation><mixed-citation xml:lang="ru">Makowska K., Nowaczyk J., Blicharz L., et al. Immunopathogenesis of atopic dermatitis: Focus on interleukins as disease drivers and therapeutic targets for novel treatments // Int J Mol Sci. 2023. Vol. 24, N 1. P. 781. doi: 10.3390/ijms24010781</mixed-citation></citation-alternatives></ref><ref id="B32"><label>32.</label><citation-alternatives><mixed-citation xml:lang="en">National Institutes of Health Cg. A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis (BREEZE-AD3). Active study: Eli Lilly and Company. 2018, March. Study identifier: NCT03334435. Available from: https://clinicaltrials.gov/study/NCT03334435. Accessed: 06.07.2023.</mixed-citation><mixed-citation xml:lang="ru">National Institutes of Health Cg. A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis (BREEZE-AD3). Active study: Eli Lilly and Company. 2018, March. Study identifier: NCT03334435. Режим доступа: https://clinicaltrials.gov/study/NCT03334435. Дата обращения: 06.07.2023.</mixed-citation></citation-alternatives></ref><ref id="B33"><label>33.</label><citation-alternatives><mixed-citation xml:lang="en">Oldhoff JM, Darsow U, Werfel T, et al. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy. 2005;60(5):693–696. doi: 10.1111/j.1398-9995.2005.00791.x</mixed-citation><mixed-citation xml:lang="ru">Oldhoff J.M., Darsow U., Werfel T., et al. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis // Allergy. 2005. Vol. 60, N 5. P. 693–696. doi: 10.1111/j.1398-9995.2005.00791.x</mixed-citation></citation-alternatives></ref></ref-list></back></article>
